Skip to main content
IDWeek 2023 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
Live Streamed
On Demand
On Demand
Back

053. Enteric Infection: Thursday, 12:15 - 1:30 p.m.

Poster Session: Enteric Infection

(655) Analysis of Microbiome Diversity and Secondary Bile Acid Synthesis Following SER-109 or Placebo in Patients with First Recurrent or Multiply Recurrent Clostridioides difficile Infection

Thursday, October 12, 2023
12:15 PM – 1:30 PM US ET
Location: Hall B + C

    Presenting Author(s)

  • CK

    Colleen R. Kelly, MD

    Associate Professor of Medicine
    Warren Alpert Medical School of Brown University
    Providence, Rhode Island, United States

    • Co-Author(s)

  • Colleen S. Kraft, MD, MSc

    Associate Professor
    Emory University
    Atlanta, GA, United States

  • TS

    Tim Straub, MS

    Seres Therapeutics, Cambridge, MA
    Cambridge, Massachusetts, United States

  • KL

    Kevin Litcofsky, PhD

    Director
    Seres Therapeutics, Inc.
    Cambridge, MA, United States

  • JW

    Jennifer R. Wortman, MS

    Vice President
    Seres Therapeutics, Cambridge, MA
    Cambridge, Massachusetts, United States

  • Stuart H. Cohen, MD

    Medical Director of Hospital Epidemiology; Division Chief, Infectious Diseases
    University of California, Davis
    Sacramento, CA, United States

  • CB

    Charles Berenson, MD

    Associate Professor of Medicine
    State University of New York at Buffalo
    Buffalo, New York, United States

  • BM

    Barbara McGovern, MD

    Vice President
    Seres Therapeutics, Inc.
    Cambridge, MA, United States

  • BH

    Brooke Hasson, PhD

    Seres Therapeutics, Cambridge, MA
    Cambridge, Massachusetts, United States

  • DH

    Dina Hot, PhD

    Aimmune Therapeutics, a Nestlé Health Science company, Brisbane, CA
    Brisbane, California, United States

  • DP

    Darrell Pardi, MD

    Professor of Medicine
    Mayo Clinic
    Rochester, MN, United States

  • CF

    Christopher Ford, PhD (he/him/his)

    Vice President
    Seres Therapeutics, Inc
    Cambridge, Massachusetts, United States

  • MH

    Matthew Henn, PhD

    EVP, Chief Scientific Officer
    Seres Therapeutics, Cambridge, MA
    Cambridge, Massachusetts, United States